1. Home
  2. MLYS vs RGR Comparison

MLYS vs RGR Comparison

Compare MLYS & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • RGR
  • Stock Information
  • Founded
  • MLYS 2019
  • RGR 1949
  • Country
  • MLYS United States
  • RGR United States
  • Employees
  • MLYS N/A
  • RGR N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • RGR Ordnance And Accessories
  • Sector
  • MLYS Health Care
  • RGR Industrials
  • Exchange
  • MLYS Nasdaq
  • RGR Nasdaq
  • Market Cap
  • MLYS 526.1M
  • RGR 610.8M
  • IPO Year
  • MLYS 2023
  • RGR N/A
  • Fundamental
  • Price
  • MLYS $10.46
  • RGR $35.54
  • Analyst Decision
  • MLYS Strong Buy
  • RGR
  • Analyst Count
  • MLYS 2
  • RGR 0
  • Target Price
  • MLYS $30.00
  • RGR N/A
  • AVG Volume (30 Days)
  • MLYS 263.5K
  • RGR 126.1K
  • Earning Date
  • MLYS 03-20-2025
  • RGR 02-19-2025
  • Dividend Yield
  • MLYS N/A
  • RGR 1.94%
  • EPS Growth
  • MLYS N/A
  • RGR N/A
  • EPS
  • MLYS N/A
  • RGR 1.73
  • Revenue
  • MLYS N/A
  • RGR $520,485,000.00
  • Revenue This Year
  • MLYS N/A
  • RGR N/A
  • Revenue Next Year
  • MLYS N/A
  • RGR $4.81
  • P/E Ratio
  • MLYS N/A
  • RGR $20.50
  • Revenue Growth
  • MLYS N/A
  • RGR N/A
  • 52 Week Low
  • MLYS $8.58
  • RGR $34.11
  • 52 Week High
  • MLYS $16.91
  • RGR $48.20
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 51.57
  • RGR 46.59
  • Support Level
  • MLYS $9.81
  • RGR $34.98
  • Resistance Level
  • MLYS $10.79
  • RGR $36.57
  • Average True Range (ATR)
  • MLYS 0.62
  • RGR 0.68
  • MACD
  • MLYS 0.15
  • RGR 0.02
  • Stochastic Oscillator
  • MLYS 100.00
  • RGR 27.32

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About RGR Sturm Ruger & Company Inc.

Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The Company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.

Share on Social Networks: